The proPSMA trial stands out, in which 302 patients with high-risk PCa were analyzed and in which they wanted to compare conventional imaging techniques versus [68Ga]Ga-PSMA-11 PET/CT, demonstrating that PSMA PET had a higher efficacy in diagnosis (92% versus 65% for TIC), higher sensitivity (85% versus. The gene discussed is FOLH1; the disease is posterior cortical atrophy.